Martydg, probably are no examples of such a situation as in 30 years of investing I have not seen any. The 'tree you are barking up' just talks and really seems to not have any comparable situations to back up what is said, just a group of posters that like to agree, again with no such prior examples but people like to hear and read what they would like to have happen ignoring reality.
CVM is not a good example as they failed the primary endpoint and trying to make the best of a success in a secondary endpoint. Suprisingly they still trade in double digits.
I at least think and hope that cvm is not a good example but DI was apparently comparing nwbo to them. I expect good data from nwbo but perhaps is still a problem with SAP. I was discussing with a coinvestor yesterday and they were concerned as none of our group can find anything comparable in our investing time - good data (we think/hope) and 14 months of silence. That is our hope (a SAP issue) as we really want the data to be good and in any normal situation a company puts it out there to the world and it generates interest excitement and momentum - all good for the shareholders and patients needing help. Sure the AFs of the world try to shoot it down but good data speaks for itself. If you can, look at the history of AVNR, AMRN, and exas all had good data had challenges from the AF types but did well and got pretty rapid regulatory approval (within a year or so). AMRN eventually did poorly due to a patent trial. Those are real examples and I don't think the one you are questioning or his followers will give you any examples as to my knowledge there are none - just talk as if there are and this is 'normal.
So we wait, hit another 52 week low but did get a little bounce. I still hope for a much better 2022. Perhaps in December we might get a first look at the ucla combination trial data.
Good luck
Market Data 
Markets 
AI
